This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osenga, K. L. Articles by Sondel, P. M. Search for Related Content PubMed PubMed Citation Articles by Osenga, K. L. Articles by Sondel, P. M.

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Authors' Affiliations: ¹ The University of Wisconsin-Madison, Madison, Wisconsin; ² Children's Hospital of Los Angeles, Los Angeles, California; ³ University of California-San Francisco, San Francisco, California; ⁴ Stanford University, Stanford, California; ⁵ Children's Oncology Group, Arcadia, California; ⁶ Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ⁷ The Scripps Research Institute, La Jolla, California; and ⁸ EMD Lexigen Research Center, Billerica, Massachusetts

Requests for reprints: Paul M. Sondel, K4/448 UWCCC, 600 Highland Avenue, Madison, WI 53792, Phone: 608-263-9069; Fax: 608-263-4226; E-mail: pmsondel{at}humonc.wisc.edu.

Purpose: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors.

Experimental Design: Twenty-seven pediatric patients with recurrent/refractory neuroblastoma and one with melanoma were treated with a humanized anti-GD2 monoclonal antibody linked to human interleukin 2 (IL-2). Cohorts of patients received hu14.18-IL2, administered i.v. over 4 hours for three consecutive days, at varying doses. Patients with stable disease, partial, or complete responses were eligible to receive up to three additional courses of therapy.

Results: Most of the clinical toxicities were anticipated and similar to those reported with IL-2 and anti-GD2 monoclonal antibody therapy and to those noted in the initial phase I study of hu14.18-IL2 in adults with metastatic melanoma. The maximal tolerated dose was determined to be 12 mg/m²/d, with agent-related dose-limiting toxicities of hypotension, allergic reaction, blurred vision, neutropenia, thrombocytopenia, and leukopenia. Three patients developed dose-limiting toxicity during course 1; seven patients in courses 2 to 4. Two patients required dopamine for hypotension. There were no treatment-related deaths, and all toxicity was reversible. Treatment with hu14.18-IL2 led to immune activation/modulation as evidenced by elevated serum levels of soluble IL-2 receptor (sIL2R) and lymphocytosis. The median half-life of hu14.18-IL2 was 3.1 hours. There were no measurable complete or partial responses to hu14.18-IL2 in this study; however, three patients did show evidence of antitumor activity.

Conclusion: Hu14.18-IL2 (EMD 273063) can be administered safely with reversible toxicities in pediatric patients at doses that induce immune activation. A phase II clinical trial of hu14.18-IL2, administered at a dose of 12 mg/m²/d x 3 days repeated every 28 days, will be done in pediatric patients with recurrent/refractory neuroblastoma.

This article has been cited by other articles:

				G.-H. Jin, T. Hirano, and M. Murakami Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation Int. Immunol., June 1, 2008; 20(6): 783 - 789. [Abstract] [Full Text] [PDF]

				T.-H. Huang, K. R. Chintalacharuvu, and S. L. Morrison Targeting IFN-{alpha} to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities J. Immunol., November 15, 2007; 179(10): 6881 - 6888. [Abstract] [Full Text] [PDF]

				Y. Zeng, N. Huebener, S. Fest, S. Weixler, U. Schroeder, G. Gaedicke, R. Xiang, A. Schramm, A. Eggert, R. A. Reisfeld, et al. Fractalkine (CX3CL1)- and Interleukin-2-Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells Cancer Res., March 1, 2007; 67(5): 2331 - 2338. [Abstract] [Full Text] [PDF]